Pricing Log in Create free account
Friday 6 November 2026 Export IMNM’s income statement to Excel — free account

Immunome, Inc.

IMNM Healthcare Biotechnology

Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024.

Revenue
+69.8%
EPS
−30.0%
Free cash flow
−27.0%

Quarter to June 2026, against a year earlier

18.78 0.87 +4.86%
Market cap
$2.1B
P/E
0.0×
Fwd P/E
−7.6×
Dividend yield
—
F-score
4/9
Altman Z
21.57
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Immunome, Inc. (IMNM) Total debt

Alert me on Total debt

Immunome, Inc.'s total debt at the end of fiscal 2022 was $62.0K, down 87.6% from $500.0K in fiscal 2020. At the end of the quarter to 30 September 2023 it was $228.0K. Immunome, Inc. ranks 463rd of 569 Biotechnology companies by total debt.

Total debt, annual

Embed this chart

Annual newest first

Period Total debt Change
FY2022 $62.0K (87.60%)
FY2020 $500.0K (11.35%)
FY2019 $564.0K (52.04%)
FY2018 $1.2M —

Quarterly newest first

Period Total debt Change
Sep 2023 $228.0K 26.67%
Jun 2023 $180.0K 190.32%
Dec 2022 $62.0K (65.36%)
Sep 2022 $179.0K (4.79%)
9 more quarters

Total debt against peers

Company Total debt
BHVN Biohaven Ltd. compare $264.3M
ADMA ADMA Biologics Inc compare $198.9M
VCEL Vericel Corporation compare $85.1M
VERA Vera Therapeutics, Inc. compare $75.2M
AUPH Aurinia Pharmaceuticals Inc compare $39.0M
PVLA Palvella Therapeutics, Inc. compare $12.3M
LKFT Lakefront Biotherapeutics - Sponsored ADR compare $5.5M
CLDX Celldex Therapeutics, Inc. compare $1.2M
IMNM Immunome, Inc. $228.0K

What Total debt is

Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.

Long Term Debt (Total) + Current Part of Debt

The full definition of Total debt →

More on IMNM